About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
ORAZAMIDE OROTATE (ID 26959) shows a complex, multi‑pathway biochemical interaction profile involving modulation of enzyme‑regulated catalytic cycles, receptor‑level signalling networks, intracellular ion dynamics, mitochondrial respiratory control, redox‑balance adaptation, cytoskeletal organisation and transcription‑factor regulatory behaviour. Its physicochemical structure supports direct or indirect interaction with catalytic residues, allosteric pockets, membrane‑spanning receptors, signalling intermediates and structural proteins, enabling influence over second‑messenger pathways (Ca²⁺, cAMP, IP₃, DAG), phosphorylation kinetics, ROS generation and mitochondrial ATP‑synthesis efficiency.
Depending on concentration, exposure duration and biological substrate, ORAZAMIDE OROTATE may shift metabolic routing, alter vesicular transport, influence chromatin accessibility, modify transcriptional clusters, or recalibrate mitochondrial stress‑response thresholds across diverse experimental models.
Benefits and Advantages
Common applications in research environments include:
- High‑resolution receptor–ligand interaction analysis and molecular docking validation
- Enzyme‑kinetic dissection and catalytic‑pathway reconstruction
- Mitochondrial‑performance assays, redox‑stress modelling and ATP‑flux quantification
- Multi‑omics integration: transcriptomics, metabolomics, proteomics, phosphoproteomics
- Cytoskeletal‑dynamics studies involving actin, tubulin and membrane‑tension regulation
- Apoptosis, autophagy, necroptosis, ferroptosis and stress‑response pathway mapping
- SAR (structure–activity relationship) investigation and molecular‑optimisation workflows
- Preclinical pharmacodynamic modelling and mechanistic dose‑response assays
Side Effects and Risks
Potential laboratory‑observed risks include:
- ROS accumulation and oxidative‑stress imbalance
- Mitochondrial hyperactivation or respiratory‑chain suppression
- Disruption of Ca²⁺/Na⁺/K⁺ ionic homeostasis and ion‑channel behaviour
- Unintended receptor cross‑activation or inhibitory interference
- Cyto‑architectural destabilisation, membrane fragility or impaired trafficking
- Dose‑dependent cytotoxicity and activation of apoptosis/autophagy signalling
- Transcriptional and epigenetic instability under prolonged exposure
- Inflammatory pathway activation (NF‑κB, MAPK, JNK)
Use exclusively under controlled laboratory conditions, following strict biosafety and handling protocols.
Datasheet
| Molecular Formula | C9H12N6O5 |
|---|---|
| Molecular Weight | 284.23 g/mol |
| CAS Number | 2574-78-9 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | less than 1 mg/mL at 68 °F (NTP, 1992) |
| Purity | Purity information is available upon request (COA). |
| Synonym | orazamide orotate; 4-amino-1H-imidazole-5-carboxamide,2,4-dioxo-1H-pyrimidine-6-carboxylic acid,dihydrate |
| IUPAC/Chemical Name | 4-amino-1H-imidazole-5-carboxamide;2,6-dioxo-1,3-diazinane-4-carboxylic acid |
| InChl Key | LNOLUKWCIVXNDY-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C5H6N2O4.C4H6N4O/c8-3-1-2(4(9)10)6-5(11)7-3;5-3-2(4(6)9)7-1-8-3/h2H,1H2,(H,9,10)(H2,6,7,8,11);1H,5H2,(H2,6,9)(H,7,8) |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
